CFPCLearn’s primary care focused library includes a variety of content including evidence summaries, videos, podcasts and interactive learning courses to support clinicians in their practice.
Most Recent Tools for Practice
Tools for Practice #392 Mission Slimpossible, Part 3: Tirzepatide for weight loss
Is tirzepatide effective for weight loss?
Tirzepatide 10-15mg/week results in ~15-20% weight loss versus 3% placebo at 72 weeks. Most patients on tirzepatide lose at least 10% body weight (78-84% versus ~20% placebo). Weight regain occurs when medication stopped. More weight loss occurs with tirzepatide versus semaglutide (~20% versus ~14%) based on one open-label, tirzepatide-sponsored randomized controlled trial (RCT). Read More
Tools for Practice #386 – The Bland Supremacy: Salt and cardiovascular disease
Does reducing sodium intake or substituting table salt with sodium-potassium alternatives improve cardiovascular outcomes?
Based on one large randomized, controlled trial (RCT) in patients with hypertension/previous stroke with above average daily salt intake (example 4.8 g/day), replacing table salt with a salt substitute may decrease mortality (from ~4.5% to ~4%) and stroke (from ~3.5% to 3%) per year. Whether reducing sodium by other means reduces mortality or cardiovascular events is unknown. Read More
Tools for Practice #383 – A single dose for treating yeast infections: Is it really this simple?
Does route or duration of antifungals matter when treating uncomplicated vulvovaginal candidiasis in non-pregnant women?
Route and duration do not impact efficacy; only a single dose of oral fluconazole or intravaginal antifungal (example clotrimazole) is needed. Patient preference should guide treatment choice. Read More
Tools for Practice #382 – Exercise for Parkinson’s Disease: More movement = Better movement?
How effective is exercise in Parkinson’s disease?
In patients with Parkinson’s Disease, exercise results in clinically meaningful improvements in motor symptoms similar to changes seen with medications (4-9 points better on a 108-point scale) compared to control over 1-6 months. It doesn’t provide clear improvements in quality of life. Six more patients out of 100 who exercise will avoid one or more falls over 6-12 months compared to control. Read More
Tools for Practice #381 – Pharm for Fibro, Round 2: Can gabapentinoids ease the pain?
Do gabapentinoids reduce pain in patients with fibromyalgia?
About 40% of people with fibromyalgia on pregabalin 300-600mg/day experience a meaningful reduction in pain (pain reduced by ≥30%) versus 30% on placebo at 8-14 weeks. Lower doses (example: 150mg) may not be effective; however, higher doses cause more harm, with up to ~30% of people stopping due to side effects (versus 10% on placebo). Based on one small randomized, controlled trial (RCT), gabapentin is also effective. Read More

Congratulations to PEER's Tina Korownyk: Alberta Family Physician of the Year
PEER Director, Dr. Tina Korownyk was awarded the 2023 Alberta Family Physician of the year at the annual Family Medicine Forum gala in Montreal, Quebec on November 10. The PEER team joined Tina to celebrate her achievement as a wonderful physician and leader in primary care. Congratulations Tina!

PEER Values
When creating primary care education and programs, the PEER team focuses on minimizing bias, patient orientated outcomes, shared decision making, collaboration and most importantly simplicity.
Who is PEER?
Patients, Experience, Evidence and Research (PEER) was formed between a group of primary care providers who shared a common belief that evidence should be made accessible to all primary care providers.
